Rosacea Clinical Trial
Official title:
Effectiveness of CGB-400 (Cosmetic) for the Reduction of Facial Redness
Verified date | August 2020 |
Source | CAGE Bio Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Open-label multicenter study using CGB-400 Gel (cosmetic) to reduce facial redness
Status | Completed |
Enrollment | 25 |
Est. completion date | April 18, 2019 |
Est. primary completion date | April 18, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Outpatient, male or female of any race, 18 years of age or older. Female subjects of childbearing potential must have a negative UPT at Baseline and practice a reliable method of contraception throughout the study. 2. Facial redness associated with rosacea. 3. Facial redness (IGA-R) score of 2 or 3 (i.e., mild or moderate). 4. Absence of any skin conditions that could interfere with the visual erythema assessments. 5. Willing to forego any other topical or non-topical treatment on the study areas during treatment (other than sun protection or the study specified face wash and moisturizer). 6. Willing to use the provided skincare regimen (e.g., face wash and moisturizer) over the duration of the study. 7. Sign the IRB-approved ICF (which includes HIPAA) prior to any study-related procedures being performed. Exclusion Criteria: 1. Known hypersensitivity or previous allergic reaction to any constituent of the Investigational Products (i.e., essential oils, fragrance, choline, phosphatidylcholine, etc.). 2. Any transient flushing syndrome. 3. History of basal cell carcinoma within 6 months of Visit 1. 4. History or presence of a skin condition/disease that is located in the treatment area(s) and might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, psoriasis, significant actinic damage, vitiligo, open wounds, infection, etc.). 5. Diagnosis of severe rosacea, ocular rosacea, rhinophymatous rosacea, or acne fulminans at Baseline. 6. Blepharitis/meibomianitis requiring systemic treatment by an ophthalmologist. 7. Uncontrolled systemic disease. 8. Foreseen unprotected and intense/excessive UV exposure during the course of the study. 9. Use of any of the following concomitant medications/procedures: - Cosmetic and/or OTC products for redness reduction and/or skin clearing - Topical medications for rosacea - Systemic antibiotics or corticosteroids - Topical antibiotics, corticosteroids, or antiparasitic agents - Intense/excessive ultraviolet (UV) radiation - Phototherapy, energy-based therapy, facials, chemical peels, microdermabrasion 10. Exposure to any other investigational drug/device within 30 days prior to study entry. |
Country | Name | City | State |
---|---|---|---|
United States | Cage Bio Investigative Site 3 | Edgewater | Florida |
United States | Cage Bio Investigative Site 1 | Fremont | California |
United States | Cage Bio Investigative Site 2 | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
CAGE Bio Inc. | ethica Clinical Research Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Investigator's Global Assessment of Redness (IGA-R) | 5-point scale (0: no redness; 1: slight redness; 2: Definite redness; 3: Marked redness and 4: Fiery redness) | 4 weeks | |
Secondary | Investigator's Global Assessment of Redness (IGA-R) | 5-point scale (0: no redness; 1: slight redness; 2: Definite redness; 3: Marked redness and 4: Fiery redness) | Day 0, Week 1, Week 2 | |
Secondary | Patient Global Assessment | 5-point scale (0: excellent effectiveness; 1: good effectiveness; 2: Effective; 3: No significant benefit and 4: No benefit at all) | Week 1, Week 2, Week 4 | |
Secondary | Bumps/Blemishes Count | Numerical count of Bumps/Blemishes | Day 0, Week 1, Week 2, Week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05597462 -
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
|
Phase 1 | |
Completed |
NCT02601963 -
Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT02249065 -
Mirvaso in Use Study
|
Phase 4 | |
Completed |
NCT02292797 -
Assessment of the Rosacea Prevalence in the General Population
|
N/A | |
Completed |
NCT01659853 -
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
|
Phase 3 | |
Completed |
NCT01426269 -
Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo
|
Phase 4 | |
Completed |
NCT00991198 -
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
|
Phase 2 | |
Terminated |
NCT04336163 -
Skin Imaging to Inform Laser Treatments
|
N/A | |
Recruiting |
NCT04108897 -
Analysis of the Microbiome in Rosacea
|
Early Phase 1 | |
Completed |
NCT03872050 -
Deep Phenotyping of Rosacea and Migraine
|
||
Active, not recruiting |
NCT06033352 -
Potassium-titanyl Phosphate (KTP) Laser vs KTP Laser and Ivermectin Cream for Facial Rosacea
|
Phase 2 | |
Completed |
NCT03263273 -
Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea
|
Phase 2 | |
Completed |
NCT04508205 -
CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes
|
Phase 1 | |
Completed |
NCT05094700 -
A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants
|
N/A | |
Active, not recruiting |
NCT03211585 -
EVALUATION OF THE EFFECT OF THE PERFECTA V-BEAM LASER ON ROSACEA
|
N/A | |
Completed |
NCT02576860 -
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
|
Phase 3 | |
Completed |
NCT02637232 -
Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
|
||
Completed |
NCT02576847 -
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
|
Phase 3 | |
Completed |
NCT02583009 -
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea
|
Phase 2 | |
Completed |
NCT01993446 -
A Safety and Efficacy Study of DRM02 in Subjects With Rosacea
|
Phase 2 |